Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 60, Issue 2, 2003, Pages 105-110

  Powell, D S ^a   Maksoud, H ^a   Charge S B P ^a   Moffitt, J H ^a   Desai, M ^a   Da Silva Fihlo, R L ^a   Hattersley, A T ^b   Stratton, I M ^a   Matthews, D R ^a   Levy, J C ^a   Clark, A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b School of Postgraduate Medicine and Health Sciences   (United Kingdom)

Author keywords

Amyloid; Apolipoprotein E; Diabetes; Genetics; Islet

Indexed keywords

AMYLIN; APOLIPOPROTEIN E; DNA;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET DELTA CELL; PROTEIN LOCALIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0037404763     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(02)00281-4     Document Type: Article

References (30)

1. Westermark P. Amyloid and polypeptide hormones: what is their interrelationship? Amyloid: Int. J. Exp. Clin. Invest. 1:1994;47-60.
2. Clark A., Wells C.A., Buley I.D., et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in Type 2 diabetes. Diabetes Res. Clin. Pract. 9:1988;151-159.
3. Schneider H.M., Storkel S., Will W. Das amyloid der Langerhansschen inseln und seine beziehung zum diabetes mellitus. Dtsch med Wschr. 105:1980;1143-1147.
4. Röcken C., Linke R.P., Saeger W. Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch. A Pathol. Anat. 421:1992;339-344.
5. de Koning E.J.P., Bodkin N.L., Hansen B.C., Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia. 36:1993;378-384.
6. O'Brien T.D., Hayden D.W., Johnson K.H., Fletcher T.F. Immunohistochemical morphometry of pancreatic endocrine cells in diabetic normoglycaemic glucose-intolerant and normal cats. J. Comp. Pathol. 96:1986;357-369.
7. Clark A., Cooper G.J.S., Lewis C.E., et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet. 2:1987;231-234.
8. Sanke T., Hanabusa T., Nakano Y., et al. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 34:1991;129-132.
9. Higham C.E., Jaikaran E.T.A.S., Fraser P.E., Gross M., Clark A. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470:2000;55-60.
10. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., Johnson K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. 84:1987;3881-3885.
11. Fraser P.E., McLachlan D.R., Surewicz W.K., et al. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J. Mol. Biol. 244:1994;64-73.
12. Kisilevsky R. Heparan sulphate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor or the tip of a more fundamental process. Lab. Invest. 63:1990;589-591.
13. Boot M., Hawkins P.N., Bickerstaff M.C., et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 3:1997;855-859.
14. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:1992;235-238.
15. Mahley R.W. Apolipoprotein E: cholesterol transport protein with an expanding role in cell biology. Science. 240:1988;622-630.
16. Siest G., Pillot T., Régis-Bailly A., et al. Apolipoprotein E: an important gene and protein to follow in Laboratory Medicine. Clin. Chem. 41:1995;1068-1086.
17. Shriver M.D., Boerwinkle E., Hewett-Emmett D., Hanis C.L. Frequency and effects of apolipoprotein E polymorphism in Mexican-American NIDDM subjects. Diabetes. 40:1991;334-337.
18. Taylor R.W., Stewart M.W., Avery P.J., et al. Apolipoprotein E and familial non-insulin dependent diabetes mellitus. Lancet. 344:1994;406.
19. Eto M., Watanabe K., Makino I. Relationship of metabolic control and body weight to hypercholesterolaemia in NIDDM patients with apolipoprotein E4. Diabetes Care. 14:1991;127-129.
20. Hashim Y., Shepherd D., Wiltshire S., Holman R.R., Levy J.C., Clark A., Cull C.A. Butrylcholinesterase K variant on chromosome 3q is associated with type 2 diabetes in white caucasian subjects. Diabetologia. 44:2001;2227-2230.
21. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand S., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
22. Lambert J.C., Araria-Goumidi L., Myllykangas L., et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology. 59:2002;59-66.
23. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 372:1994;92-94.
24. Esler W.P., Marshall J.R., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., Maggio J.E. Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid: J. Protein Folding Disord. 9:2002;1-12.
25. Chargé S.B.P., Esiri M.M., Bethune C.A., Hansen B.C., Clark A. Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J. Pathol. 179:1996;443-447.
26. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31:1990;545-548.
27. Turner R.C., Stratton I., Horton V., et al. UKPDS 25: autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type 2 diabetes. Lancet. 350:1997;1228-1293.
28. J. Vidal, C.B. Verchere, S. Andrikopoulous, R.L. Hull, F. Wang, S.E. Kahn., Apolipoprotein E is not required for amyloid deposition in a transgenic mouse model of Type 2 diabetes. Diabetologia, (2003, in press).
29. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene and the risk for dementia and related pathologies; the Honolulu-Asia aging study. Diabetes. 51:2002;1256-2002.
30. Kang E., Pietrzik C.U., Baum L., et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106:2000;1159-1166.